Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Pancreatic Neoplasms 2 Melanoma 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Prostatic Neoplasms 1 Neoplastic Cells, Circulating 1 Myelodysplastic Syndromes 1 Medulloblastoma 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Pancreatic Cancer 1

Interventions

Cisplatin 141 Radiotherapy 115 Cetuximab 95 Docetaxel 69 Radiotherapy, Intensity-Modulated 55 Carboplatin 47 pembrolizumab 46 Surveys and Questionnaires 46 Paclitaxel 41 Fluorouracil 39 Radiation 29 Blood Specimen Collection 27 Drug Therapy 26 Erlotinib Hydrochloride 23 Nivolumab 21 Surgical Procedures, Operative 17 Standard of Care 16 Magnetic Resonance Spectroscopy 16 Radiosurgery 14 Pemetrexed 14 Gemcitabine 14 Everolimus 13 Celecoxib 13 durvalumab 12 Low-Level Light Therapy 12 Immunohistochemistry 12 Cyclophosphamide 12 Capecitabine 12 Amifostine 12 Chemoradiotherapy 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Head and Neck Neoplasms × Digoxin × Clear all

NCT02906800 2017-10-19

DIGHANC

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡